Breaking News Bar

Business News and Information

Ascentage to Start China Trials of Bcl-2 Apoptosis Candidate

Suzhou Ascentage Pharma said its novel Bcl-2 inhibitor was approved to start two China Phase Ib/II clinical trials: one in Waldenström macroglobulinemia (WM), and the other one in multiple myeloma (MM). APG-2575 is designed to treat hematologic malignancies by selectively blocking Bcl-2 to restore the normal apoptosis process in cancer cells. The candidate has started multiple trials in China and Australia . The WM Phase Ib/II trial will be a global multicenter test with centers in Australia , China and the US . More details.... Stock Symbol: (HK: 6855) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear